Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients.
Sara De BiasiDomenico Lo TartaroAnita NeroniMoritz RauNikolaos PaschalidisRebecca BorellaElena SantacroceAnnamaria PaoliniLara GibelliniAlin Liviu CiobanuMichela CuccoreseTommaso TrentiIgnacio RubioFrancesca VitettaMartina CardiRafael Jose ArgüelloDiana FerraroAndrea CossarizzaPublished in: Nature communications (2024)
Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.
Keyphrases
- multiple sclerosis
- sars cov
- immune response
- end stage renal disease
- newly diagnosed
- ejection fraction
- single cell
- chronic kidney disease
- mass spectrometry
- prognostic factors
- ms ms
- peritoneal dialysis
- respiratory syndrome coronavirus
- induced apoptosis
- white matter
- patient reported outcomes
- rna seq
- coronavirus disease
- machine learning
- cell cycle arrest
- oxidative stress
- artificial intelligence
- signaling pathway
- diffuse large b cell lymphoma
- big data
- patient reported
- endoplasmic reticulum stress